Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HNSCC: early-phase trial registry
16 of 24 indexed HNSCC trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #686 of 28,707 conditions by registered trial count.
24 US clinical trials · 16 currently recruiting · #686 of 28,707 conditions by registered trial count
HNSCC: 24 US clinical trials tracked, 16 recruiting.
HNSCC is the subject of 24 registered US clinical trials on ClinicalTrials.gov, 16 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is Dan Zandberg, running 2 of these trials.
Enrollment posture brief
Registry condition hnscc
OPEN 16 | RECR 67% | LATE 1 | EARLY 21 | RANK #686 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
HNSCC lists 16 open slots (67% of 24 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HNSCC on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HNSCC is recruiting above its size-band peers.
16 of 24 indexed trials (66.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of HNSCC trials is spread across many organizations.
Dan Zandberg accounts for 2 of 24 trials (8.3%). 22 distinct sponsors appear on at least one study for this condition label.
-
Typical HNSCC enrolment sits around 78 participants.
Median target enrolment is 78 among the 24 trials that report a genuine target (sentinel values excluded). 13 of those (54.2%) plan for fewer than 100 participants.
-
HNSCC research is mostly interventional.
23 interventional and 1 observational studies make up this index (95.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
24 total, page 1 of 1
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
University Hospital Freiburg
NCT05337631
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Merus B.V.
NCT03526835
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech
NCT05581004
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis
NCT06657222
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
SparX Biotech(Jiangsu) Co.
NCT06259552
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
ALX Oncology
NCT07085091
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Epkin
NCT06789172
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
CJ Bioscience
NCT05877430
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Normunity AccelCo
NCT07182149
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Dan Zandberg
NCT04114136
High-Resolution PET-CT Imaging for Surgical Margin Visualization
Vanderbilt-Ingram Cancer Center
NCT06915454
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
VLP Therapeutics
NCT06736379
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT04722523
Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC
University of California, Irvine
NCT06693323
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
ImmVira Pharma Co.
NCT04370587
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
Vanderbilt-Ingram Cancer Center
NCT06819228
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen
NCT04354246
Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC
University of Cincinnati
NCT04340258
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
Washington University School of Medicine
NCT05980000
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
AgonOx
NCT05902520
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg
NCT04157985
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
University of California, San Diego
NCT03082534
De-Escalation Therapy for Human Papillomavirus Negative Disease
University of Chicago
NCT03944915
Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC
University of Colorado, Denver
NCT04042935
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 5 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on HNSCC records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HNSCC trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HNSCC page
24 registered trials, 16 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 16 HNSCC trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Dan Zandberg sponsors the most HNSCC trials on record, review their full trial history before evaluating a specific study. See Dan Zandberg's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HNSCC condition card totals 24 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.